NLS Pharma Business

The two companies will advance the development of two blood-brain barrier (BBB)-crossing recombinant enzyme replacement therapies (ERT) for lysosomal storage disorders (LSD), including alpha-mannosidosis (aMann) and Krabbe disease (KD), ultra-rare diseases that affect the central nervous system.

Camurus and Eli Lilly and Company (Lilly) have entered a collaboration and license agreement, granting Lilly exclusive, worldwide rights to the research, development, manufacture, and commercialization of long-acting incretin products for cardiometabolic health based on Camurus’ FluidCrystal technology.

Imfinzi (durvalumab) has been recommended for approval in the European Union (EU) for the treatment of adult patients with resectable muscle-invasive bladder cancer (MIBC) in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by Imfinzi as monotherapy adjuvant treatment after radical cystectomy (surgery to remove the bladder).

Orion Corporation and Shilpa Biocare Private Limited, a fully-owned subsidiary of Shilpa Medicare Limited, have entered into an agreement to commercialize Recombinant Human Albumin in Europe.

Cinclus Pharma has established a strategic alliance and licensing agreement with Zentiva for the commercialization and manufacturing of its lead asset, linaprazan glurate, in Europe.

The company has announced an agreement with the Danish Centre for AI Innovation (DCAI), the company established to run and operate Gefion, Denmark’s flagship AI supercomputer.